LLS hosts free program on peripheral T-cell lymphomas
The Leukemia & Lymphoma Society will host one of its many free telephone /web education programs this coming March 14, 2012, this one with a focus on peripheral T-cell lymphomas.
Beginning at 130 PM Eastern time and running for one hour, the program will be hosted by Steven M. Horowitz, an MD in the Hematologic Oncology division at Memorial Sloan-Kettering Cancer Center in New York City.
The program will discuss:
-- Peripheral T-cell lymphoma (PTCL)
-- Subtypes of PTCL
-- Treatment options for patients with newly diagnosed and refractory or relapsed PTCL
-- The role of clinical trials as treatment options for PTCL patients
-- PTCL information and support resources for patients, caregivers and healthcare professionals.
Register by phone? Call 877-804-2063.
By web? Click Here.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
